Business
Nuwellis’ Vivian Receives $3 Million NIH Grant to Accelerate Pediatric Platform and Strengthen Fluid-Management Portfolio
Awarded grant supports dedicated pediatric continuous renal replacement therapy (CRRT) device in development for patients between 2.5 and 20 kg where therapeutic options are scarce Company working to advance Vivian™ towards an investigational device study to support the path to US regulatory clearance MINNEAPOLIS, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Nuwellis Inc. (Nasdaq: NUWE), announced today that the National Institutes of Health (NIH) has awarded an approximately $3 million multi-year grant t
About this update from Nuwellis, Inc.
[{"type":"image","alt":"Nuwellis, Inc.","displaySize":"","headline":null,"caption":"Nuwellis, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":1280,"height":720,"url":"https://media.zenfs.com/en/globenewswire.com/d2460037586c5d451999b7d63383d34b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qlvoLO4BesKJEX5Y06A7WQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d2460037586c5d451999b7d63383d34b","width":960,"height":540},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/wkXbqpIKb.zGLhPGCQMxfA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xMzUwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/d2460037586c5d451999b7d63383d34b","width":1200,"height":675}},"lazy":false},{"type":"text","content":"Awarded grant supports dedicated pediatric continuous renal replacement therapy (CRRT) device in development for patients between 2.5 and 20 kg where therapeutic options are scarce","length":180,"tagName":"p"},{"type":"text","content":"Company working to advance Vivian™ towards an investigational device study to support the path to US regulatory clearance","length":121,"tagName":"p"},{"type":"text","content":"MINNEAPOLIS, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Nuwellis Inc. (Nasdaq: NUWE), announced today that the National Institutes of Health (NIH) has awarded an approximately $3 million multi-year grant to its development partner, Koronis Biomedical Technologies Corporation (KBT). The NIH-supported program will accelerate Vivian™, Nuwellis’ dedicated pediatric continuous renal replacement therapy (CRRT) device in development for patients under 20 kilograms, and advance core software and firmware that strengthen the company’s broader portfolio.","length":542,"tagName":"p"},{"type":"text","content":"For babies and small children with kidney failure or who require artificial kidney support, therapeutic options remain limited. Clinicians often adapt technologies built for adults, which can create challenges for the smallest patients. Vivian is being designed to meet these needs head-on with a pediatric-specific approach to precise, gentle fluid management. The program builds on the company’s Aquadex SmartFlow® technology, which is currently indicated for adults and pediatric patients 20 kg and above, and aims to extend support to children under 20 kg.","length":560,"tagName":"p"},{"type":"te...